Read by QxMD icon Read

Jung nei lai

Reury-Perng Perng, Chih-Hsin Yang, Yuh-Min Chen, Gee-Chen Chang, Meng-Chih Lin, Ruey-Kuen Hsieh, Nei-Min Chu, Ruay-Sheng Lai, Wu-Chou Su, Chao-Jung Tsao, Te-Chun Hsia, Hao-Cheng Chen, Chih-Hung Chen, Ming-Shyan Huang, Jui-Long Wang, Ming-Lin Ho, Chih-Yuan Chung, Chong-Jen Yu, Wen-Cheng Chang, Han-Pin Kuo, Chih-Teng Yu, Zhong-Zhe Lin, Woei-Yau Kao
PURPOSE: Erlotinib is the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) which has demonstrated a survival benefit in non-small-cell lung cancer (NSCLC) patients. An open label phase II study was conducted in Taiwanese patients with NSCLC to evaluate its efficacy. METHODS: Patients with proven stage IIIB/IV NSCLC who had received at least one line of standard chemotherapy or radiotherapy were enrolled into this study. All patients were given oral erlotinib, 150mg/day till disease progression...
October 2008: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"